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an animal model system to further explore the role of leptin in insulin sensitivity and energy balance in a medically relevant murine model of lipodystrophy. As a step forward in understanding the molecular mechanism(s) involved in the insulin sensitizing effect of leptin, we here describe the metabolic and molecular effects of leptin replacement in Agpat2 Ϫ / Ϫ mice and determine the functional relevance of hepatic LepR for metabolic actions of leptin in Agpat2 Ϫ / Ϫ mice by selectively deleting it from hepatocytes.
RESEARCH DESIGN AND METHODS

Animals
Generation of Agpat2 Ϫ / Ϫ mouse and genotyping is described elsewhere ( 25 ) . Mice were housed in colony cages (four per cage) and maintained on a 12 h light/12 h dark cycle and fed Teklad Mouse/Rat Diet 7002 from Harlan Teklad Premier Laboratory Diets (Madison, WI). Animals were euthanized at the end of the dark cycle by isofl urane overdose; blood and tissues were harvested in less than 1 min. All mouse housing, breeding, surgical procedures, euthanasia, and tissue collection were conducted in conformity with Public Health Service (PHS) policy and performed with the approval of the Institutional Animal Care and Use Committee at the University of Texas Southwestern Medical Center. All efforts were made to minimize animal suffering. 
Generation of Agpat2
؊
Leptin infusion
Mouse recombinant leptin (Sigma, St. Louis, MO) was dissolved in phosphate saline buffer (1 mg/ml, release rate of ~0.25/µg/h), and 100 µl was loaded into osmotic minipumps (model 1002, Alzet, Cupertino, CA). Leptin was delivered at a rate of 0.25 ± 0.05 µg/h. The pumps were subcutaneously inserted in the interscapular space under isofl urane general anesthesia. The surgical wound was closed with metal clips and the animals were allowed to recover on a heating pad. Control mice were implanted with minipumps fi lled with PBS. The minipumps were removed and replaced with new ones after two weeks. At the end of the fourth week, the animals were euthanized and blood and liver were harvested for analysis.
Pair feeding and indirect calorimetry
For pair-feeding studies in Agpat2 Ϫ / Ϫ mice, food intake was restricted in the saline-infused Agpat2 Ϫ / Ϫ mice to the same level as that of leptin-infused ones. For this, individual animals were housed in calorimetric cages (CLAMS, Columbus Instruments, Columbus, OH) and allowed to acclimate for one week. Basal food and water intake, VO 2 , VCO 2 , and locomotor activity were to the alternative splicing of a single common transcript ( 18 ) . The four short-forms (LepRa, LepRc, LepRd, and LepRf) and the one long-form (LepRb) share the extracellular and transmembrane domains as well as the fi rst 29 amino acids of the intracellular domain. Only the intracellular domain of LepRb contains a sequence motif for the binding of JAK protein kinases that is crucial for leptin signaling ( 18, 19 ) . The db/db mice, which exclusively lack the LepRb isoform ( 18, 20 ) , have an identical metabolic phenotype to that observed in db
3J
/ db 3J mice that lack all the LepR isoforms ( 21 ) and ob / ob mice, which primarily lack leptin ( 1 ), indicating that LepRb mediates most, if not all, metabolic actions of leptin.
The role of WAT in whole-body metabolic regulation has been further addressed by the observation that severe WAT defi ciency associates with the same metabolic complications of obesity. In fact, both the congenital generalized lipodystrophy (CGL) patients ( 22 ) and lipodystrophic mouse model, including aP2-tg-Srebp1c, A-ZIP/F-1 , and Agpat2 Ϫ / Ϫ mice (23) (24) (25) , develop hyperinsulinemia, diabetes mellitus, dyslipidemia, and fatty liver, indicating that both extremes of adiposity might share common pathophysiologic pathways that lead to same fi nal metabolic derangement.
The missing link in CGL patients and lipodystrophy mouse models could be the abnormal levels of some adipokines, such as leptin, due to lack of adipose tissue. This is in contrast to elevated circulating levels of leptin in obese subjects in whom the action of this hormone in the CNS appears to be impaired and is referred to as "leptinresistance" state ( 26 ) . CGL is characterized by very low levels of plasma leptin as a consequence of primary WAT defi ciency. Seminal studies reported by Brown and Goldstein ( 27 ) demonstrated that leptin supplementation results in remarkable amelioration of hyperphagia, plasma insulin, and glucose and liver triglyceride concentrations in their hypoleptinemic aP2-tg-Srebp1c lipodystrophy mouse model ( 27 ) . The clinical relevance of these observations was later corroborated by leptin supplementation in severely hypoleptinemic lipodystrophic patients ( 28 ) . These subjects responded dramatically and favorably to leptin treatment, signifi cantly improving insulin resistance and liver and plasma triglyceride levels. However, such improvements have failed to be observed in common obese subjects when infused with leptin, most likely due to resistance to the metabolic actions of this hormone ( 29 ) .
The mechanism(s) underlying leptin's insulin-sensitizing actions in both leptin-defi cient humans and rodents and the reason why obese individuals develop leptin resistance remains obscure. We recently generated and characterized a murine model of human CGL type 1 syndrome, the Agpat2 Ϫ / Ϫ mouse ( 25 ) . The AGPATs are intermediate enzymes in the pathway for the biosynthesis of glycerophospholipids (GPL) and triacylglycerol (TAG) ( 30 ) . AGPATs esterify the sn-2 position of 1-acylglycerol-3-phosphate (lysophosphatidic acid or LPA) to phosphatidic acid (PA) (31) (32) (33) . Mutations in AGPAT2 cause congenital generalized lipodystrophy in humans ( 34 ) , and Agpat2 Ϫ / Ϫ mice recapitulate all the features of lipodystrophy observed in humans, including severe hypoleptinemia, thus providing
The primers used for amplifi cation were: L-pk promoter: forward, 5 ′ -GAAGGATGCCCACTACAGCC-3 ′ and reverse, 5 ′ -TGCC TT-TGTCAGTGGGATGG-3. As a negative control, albumin pro moter was amplifi ed with the primers: forward, 5 ′ -CAAGGCC CACAC-TGA AATGC-3 ′ and reverse, 5 ′ -TGTGTGCAGAAAGA CTCGCTC-3 ′ .
Detection of glycosylated ChREBP in the liver by immunoblotting
To measure posttranslation modifi cation for ChREBP, this transcription factor was immunoprecipitated and immunoblotted with an antibody specifi c for O -linked ␤ -N -acetylglucosamine ( O -GlcNAcylation). Whole-liver protein extracts were prepared from 100 mg of individual livers (n = 4-6 per group) by homogenization in RIPA buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% NP-40, 1% sodium deoxycholate) supplemented with phosphatase inhibitors (2.5 mM Na 3 VO 4 and 2.5 mM Na 4 P 2 O 7 ) and protease inhibitor cocktail (Roche). One milligram of pooled proteins was immunoprecipitated with a ChREBP antibody (NB400-135, Novus Biologicals). Immune complexes were recovered after addition of 50 ml of protein A/G agarose-PLUS (Santa Cruz Biotechnology) and gentle centrifugation. Bound proteins were visualized by immunoblot analysis using a monoclonal antibody directed against O -linked ␤ -Nacetylglucosamine (MMS-248R, Covance).
Biochemical and hormone determinations
Liver triglycerides and cholesterol as well as plasma triglycerides, cholesterol, glucose, insulin, and leptin were measured as previously described ( 25 ) 
Statistical analysis
Plasma leptin, insulin, glucose and liver tissue triglycerides, cholesterol, and glycogen were compared by one-way ANOVA followed by Bonferroni's multiple comparison test using GraphPad Prism version 5.0 (San Diego, CA). Gene expression analysis was initially performed in pooled samples. For this, equal amounts of RNA for each experimental group were pooled and the fold change relative to control groups was determined. If the resulting fold change was greater than 1.5 or less than 0.7, individual RT-PCR was performed to determine the statistical signifi cance of these differences. Individual sample results are presented as mean ± SEM. The number of animals used for experimentation was limited because more than 80% of Agpat2
and Agpat2 Ϫ / Ϫ ;LepR hepato-ko mice die before the time of weaning, possibly because of severe hyperglycemia and dehydration ( 25 ) . For this reason, some experimental groups had only three animals. However, both the physiological determinations and the gene expression analysis show that the inter-individual variability is minimal and the differences among experimental groups are statistically signifi cant.
RESULTS
Leptin normalizes glucose, insulin, and liver triglycerides and glycogen in Agpat2
؊ / ؊ mice Agpat2 Ϫ / Ϫ mice lack both WAT and brown adipose tissue (BAT) and develop insulin resistance, diabetes mellitus, determined during this period. Osmotic minipumps, fi lled either with leptin (1 mg/ml, n = 6) or a saline solution (PBS, n = 6), were implanted in Agpat2 Ϫ / Ϫ mice at the beginning of the second week. Animals were replaced in their original calorimetric cages with unrestricted food access. In the next three weeks, food access was unlimited for the leptin-treated mice, whereas it was limited for the saline-infused ones. For the food restriction experiment, the feeders of the food-restricted group were refi lled at the beginning of the dark phase, and the amount of food consumed was calculated on the basis of individual mice body weight to that of the leptin-treated mice.
Gene expression analysis by RT-PCR
Total RNA was prepared from the mouse livers using RNA STAT-60 kit (Tel-Test Inc., Friendswood, TX). Genomic DNA in the RNA samples was eliminated by RNase free DNase digestion (Ambion, Austin, TX). cDNA was generated using TaqMan® reverse transcription kit (Applied Biosystems-Roche, Branchburg, NJ). Real-time PCR was carried out in 384-well plates, read, and analyzed using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). PCR conditions and primers used were previously reported ( 25 ) . Primers sequences are presented in supplementary Table I . Q-PCR expression levels were normalized to the expression level of cyclophilin and the fold change was estimated by the ⌬ ⌬ C T method.
Antibodies and immunoblot analysis
For ACC-1, FAS, IR, PI3K, AKT (total and phosphorylated), GSK3 ␤ (total and phosphorylated), ERK1/2 (total and phosphorylated), AMPK ␣ (total and phosphorylated), and RAP immunoblot analysis, whole-liver protein extracts were prepared from individual animals as described ( 35 ) . Equal aliquots of total protein from each liver were pooled, and 30 µg was separated in 8% SDS-PAGE, transferred onto nitrocellulose membranes, blocked, and incubated with primary and secondary antibodies. For SREBP-1, total membranes and nuclear extracts were prepared from individual mice as described ( 25 ) . Equal aliquots from each animal were pooled and separated in 8% SDS-PAGE, transferred onto nitrocellulose membranes, blocked, and incubated with primary and secondary antibodies as described ( 25 ) . The primary antibodies used were insulin receptor (IR) subunit ␤ (BD Transduction Laboratories, San Jose, CA), PI3K subunit p85 (Upstate, Lake Placid, NY), SREBP-1 ( 36 ), ChREBP (Novus Biologicals, Saint Louis, MI), and FAS and ACC1 (Genepia, Seoul, South Korea). The primary antibodies against AKT, phospho-AKT (Ser473), GSK3 ␤ , phospho-GSK3 ␤ (Ser9), ␣ AMPK, phospho-␣ AMPK (Thr172), ERK1/2 and phospho-ERK1/2 (Thr202, Tyr204) were all obtained from Cell Signaling Technology. Secondary peroxidaseconjugated donkey anti-mouse and anti-rabbit IgG were obtained from Jackson Immunoresearch (West Grove, PA) and GE Healthcare (Little Chalfont, UK), respectively. All immunoblots were visualized by SuperSignal® West Pico Chemiluminiscent Substrate (Pierce, Rockford, IL).
ChIP assay for mouse liver pyruvate kinase ( L-pk ) promoter occupancy by ChREBP
Chromatin immunoprecipitation (ChIP) assays were performed as described before ( 37 ) . Proteins were crosslinked to DNA by addition of 1% formaldehyde to ‫ف‬ 70 mg of mouse whole-liver tissue by incubating for 10 min at room temperature. Sonication was performed by eight pulses of 10 s each. Immunoprecipita
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؊ / ؊ mice 279 ( Fig. 2B, C ) . Food restriction did not modify any of these parameters in Agpat2 Ϫ / Ϫ mice, and leptin supplementation did not change insulin or glucose in wildtype mice ( Fig. 2B, 
C ). Leptin administration to Agpat2
Ϫ / Ϫ mice was also associated with signifi cant decreases in liver triglycerides and cholesterol concentrations ( Fig. 2D , E ) and signifi cant increases in hepatic glycogen content ( Fig. 2F ). Food restriction did not change liver triglycerides or cholesterol, but it did signifi cantly elevate glycogen levels in Agpat2 Ϫ / Ϫ mice ( Fig. 2F ).
Leptin partially normalizes corticosterone and thyroxine plasma levels in Agpat2 ؊ / ؊ mice Murine models of leptin defi ciency have altered levels of plasma corticosterone and thyroid hormone levels. Leptin defi cient ob / ob mouse has adrenal hypertrophy ( 39 ), increased levels of circulating corticosterone ( 40 ), low thyroidal rates of radioactive iodine uptake ( 41 ) and reduced thyroptropin and thyroid hormones circulating levels ( 42 ) . Lipodystrophic A-ZIP/F-1 mice also have elevated corticosterone levels ( 43 ); however, their hepatic steatosis, and hypertriglyceridemia ( 25 ) . As a consequence of adipose tissue defi ciency, these mice have extremely low levels of circulating leptin ( 25 ) . To study the metabolic effects as well as the molecular mediators of leptin restitution in Agpat2 Ϫ / Ϫ mice, 16-week-old male mice were infused with leptin for four weeks. Leptin did not reverse the lack of macroscopic white and brown adipose tissue in the Agpat2 Ϫ / Ϫ mice, but it resulted in signifi cant reduction of food intake in the Agpat2 Ϫ / Ϫ mice (compare Fig. 1A , before leptin infusion, with Fig. 1D , after leptin infusion). Since metabolic changes in the Agpat2 Ϫ / Ϫ mice could entirely be dependent on reductions in energy intake, a group of Agpat2 Ϫ / Ϫ mice was infused with saline and their food intake was restricted to the level of Agpat2
leptin-infused mice ( Fig. 1G ). Leptin infusion did not affect oxygen consumption rate (VO 2 , data not shown) or calculated heat production ( Fig. 1B , E, H ), but it normalized locomotor activity in the Agpat2 Ϫ / Ϫ mice ( Fig. 1F, I ).
As shown in the Fig. 2A , leptin infusion signifi cantly elevated plasma leptin levels in both wild-type and Agpat2 Ϫ / Ϫ mice, resulting in decreased insulin and glucose levels in Ϫ / Ϫ mice were housed in metabolic cages, and food intake, VO 2 , VCO 2 , and locomotor activity were recorded as detailed in Research Design and Methods. Animals were divided in two cohorts: A (shown in blue) and B (shown in red). In panels A, B. and C. both cohorts remained untreated. In panels D, E, and F, animals in cohort A were implanted with osmotic mini-pumps fi lled with a saline buffer (PBS), whereas animals in cohort B were implanted with mini-pumps fi lled with a leptin solution (1 mg/ml) with six mice in each group. In panels G, H, and I, both cohorts remained with the same infusions as in panels D, E, and F, but animals in cohort A were additionally subjected to food restriction, whereas animals in cohort B were fed ad libitum. Panels A, D, and G correspond to accumulated food intake. Panels B, E, and H show the calculated heat production based on body weight corrected for VO 2 and respiratory quotient (data not shown). Panels C, F, and I correspond to total locomotor activity on the X-axis of the metabolic cages. The data were compared by two-way ANOVA. *** P < 0.05. metabolic effects do not depend on food intake. Leptin signifi cantly reverses abnormal plasma glucocorticoid and thyroxine levels in the Agpat2 Ϫ / Ϫ mice; however, the complete normalization was not achieved.
Leptin ameliorates the exaggerated hepatic expression of lipogenic genes in the Agpat2
To study the molecular mechanisms by which leptin improves insulin sensitivity and hepatic steatosis in Agpat2 Ϫ / Ϫ mice, hepatic mRNA expression levels of lipogenic and oxidative enzymes as well as key transcriptional regulators of de novo lipogenesis were quantifi ed in leptin-treated Agpat2 Ϫ / Ϫ mice. As shown in Table 1 , leptin supplementation, but not food restriction, was associated with a signifi cant decrease of Acc1 , Fas , Scd1 and Elovl6 mRNA levels in the livers of Agpat2 Ϫ / Ϫ mice. These reductions at the mRNA level were consistent with lower ACC-1 and FAS protein concentrations in the livers of leptin-treated Agpat2 Ϫ / Ϫ mice ( Fig. 4A ).
thyroid hormones and thyroid functional tests remain normal ( 43 ) . In contrast, Agpat2 Ϫ / Ϫ mice have markedly decreased plasma thyroxine (T4) level compared with their wild-type littermates (0.5 ± 0.2 g/dl versus 3.8 ± 0.3 g/dl, respectively, Fig. 3A ). Agpat2 Ϫ / Ϫ mice also have markedly increased plasma corticosterone (9.3 ± 2.1 ng/ml versus 0.3 ± 0.2 ng/ml in wild-type mice, Fig. 3B ). Leptin infusion, but not food restriction, signifi cantly reversed both hormone abnormalities in these animals ( Fig. 3 ) . However, the corrective effect of leptin was more pronounced for T4 than for corticosterone, which remained ‫ف‬ 13-fold higher in the leptin-treated Agpat2 Ϫ / Ϫ mice compared with the wild-type mice (3.8 ± 0.5 ng/ml versus 0.3 ± 0.2 ng/ml). Considered together, our fi ndings indicate that leptin positively infl uences insulin sensitivity in the lipodystrophic AGPAT2 defi cient mice, restoring liver triglycerides, cholesterol and glycogen to normal levels, and that these Leptin, hepatic steatosis, and insulin resistance in Agpat2 ؊ / ؊ mice 281
Mgat1 mRNA levels ( Table 1 ), suggesting that this hormone could also reduce liver triglycerides by decreasing DAG availability.
The above results indicate that leptin may decrease liver triglycerides in AGPAT2 defi cient mice by ameliorating both exaggerated de novo lipogenesis and DAG formation. Our results do not support the hypothesis that leptin increases liver fatty acid oxidation rates in absence of AGPAT2.
Transcriptional activity of ChREBP is increased in livers of Agpat2
؊ / ؊ mice and is normalized by leptin infusion
The molecular basis of the exaggerated hepatic de novo lipogenesis in the livers of Agpat2 Ϫ / Ϫ mice remains unclear. Fig. 4C ), supporting the lack of role for Srebp-1c in the exaggerated hepatic de novo lipogenesis of
Chrebp is a basic helix-loop-helix transcription factor that also regulates hepatic lipogenesis ( 49 ) . In contrast to Srebp-1c , Chrebp is not regulated by insulin but rather it responds to changes in pentose phosphate pathway metabolites levels ( 49 ) and glucose level. Importantly, although the transcriptional program regulated by ChREBP extensively overlaps with that of SREBP-1c ( 49 ) , liver pyruvate kinase ( L-pk) is exclusively regulated by ChREBP and can be used to discriminate the actions of one transcription factor over the other.
In Agpat2 Ϫ / Ϫ mice, hepatic ChREBP is decreased at both mRNA and total nuclear protein levels and leptin administration is associated with higher ChREBP protein levels in these animals, with a more pronounced normalizing effect on It has been reported that leptin activates fatty acid oxidation, thus decreasing hepatic triglyceride concentration ( 44, 45 ) . To evaluate whether enhanced fatty acid oxidation rates explained the diminished liver triglyceride levels of leptin-treated Agpat2 Ϫ / Ϫ mice, mRNA levels of several genes involved in mitochondrial and peroxisomal fatty acid oxidation pathways were quantifi ed. No differences were detected in Cpt1a , Lcad , Mcad , or Acox1 mRNA levels between leptin and saline-infused Agpat2 Ϫ / Ϫ mice ( Table 1 ) .
Furthermore, leptin supplementation resulted in lower mRNA levels of hepatic Ucp2 in Agpat2 Ϫ / Ϫ mice compared with saline-infused Agpat2 Ϫ / Ϫ mice, suggesting that liver fatty acid oxidation rates could actually be diminished by leptin. Expression of several transcription factors associated with liver lipid metabolism remained unchanged ( Table 1 ) . Liver mRNA levels of Fgf21 , a recently identifi ed hormone associated with starvation-feeding cycle, was increased 70.4-fold in the saline-treated Agpat2 Ϫ / Ϫ relative to saline-infused wild-type mice; leptin supplementation was associated with a 23-fold decrease of Fgf21 mRNA levels in Agpat2 Ϫ / Ϫ mouse livers ( Table 1 ) .
In skeletal muscle, leptin promotes fatty acid oxidation by stimulating phosphorylation and activation of AMPactivated protein kinase (AMPK). AMPK activation results in decreased ACC-1 activity, lower malonyl-CoA levels and enhanced mitochondrial fatty acid ␤ -oxidation ( 46 ) . To assess the effects of leptin on hepatic AMPK levels in Agpat2 Ϫ / Ϫ mice, phosphorylation of ␣ catalytic subunit of AMPK ( ␣ AMPK) was examined by immunoblot analysis. As shown in Fig. 4B , infusion of leptin did not change hepatic levels of phospho-␣ AMPK, suggesting that in AGPAT2 defi cient mice leptin did not repress ACC-1 activity by AMPK-dependent mechanisms and that it did not stimulate fatty acid oxidation. Others have reported similar lack of AMPK-effects of leptin in cardiac muscle ( 47 ) and liver ( 45 ) .
Mgat1 (also known as Mogat1 ), which catalyzes sn -1 ( 3 )-and sn -2-monoacylgycerol acylation is not expressed in the normal adult mouse liver but is detectable in the livers of Agpat2 Ϫ / Ϫ mice, providing an alternative pathway for hepatic diacylglycerol (DAG) and, ultimately, triacylglycerol synthesis ( 25 ) . In these mice, leptin signifi cantly reduced O -linked ␤ -N-acetylglucosamine ( O -GlcNAcylation) has been recently recognized as a modifi cation that increases both nuclear localization and transcriptional activity of ChREBP in the mouse liver ( 37 ). While we did not observe increased L-pk promoter occupancy by ChREBP ( Fig. 5B ) , immunoblot analysis revealed that the livers of Agpat2 Ϫ / Ϫ mice do have increased abundance of O -GlcNAcylated ChREBP and that leptin treatment further elevate this modifi cation ( Fig. 5C ) .
Considered together, these fi ndings suggest that leptin reduces the expression of lipogenic enzymes and hepatic triglyceride accumulation by decreasing ChREBP transcriptional activity. There is clearly a striking lack of concordance between total ChREBP nuclear levels, L-pk promoter association and O -GlcNAcylation and its transcriptional activity that will require further investigation.
ChREBP nuclear protein than on its mRNA concentration ( Table 1 , Fig. 5A ). Paradoxically, the opposite happens to L-pk : it is elevated in saline-infused Agpat2 Ϫ / Ϫ mice, indicating increased ChREBP transcriptional activity, but it is reduced in leptin-infused ones, indicating decreased ChREBP activation ( Table 1 ) .
Leptin does not affect ChREBP association with L-pk promoter but increases ChREBP O -GlcNAcylation
To address the paradoxical effect of leptin on ChREBP nuclear abundance and its transcriptional activity in the livers of Agpat2 Ϫ / Ϫ mice, the binding of ChREBP to L-pk promoter was assessed by ChIP. As shown in Fig. 5B , we observed no differences in the recruitment of ChREBP to the L-pk promoter between Agpat2 +/+ and Agpat2 Ϫ / Ϫ mice, and neither food restriction or leptin treatment could modify this association. Leptin, hepatic steatosis, and insulin resistance in Agpat2 ؊ / ؊ mice 283 mRNA levels in the skeletal muscle compared with the wild-type mice ( Table 2 ) . Leptin, as well as food restriction, signifi cantly lowered Acc1 mRNA expression in Agpat2 Ϫ / Ϫ mice compared with the saline-infused Agpat2 Ϫ / Ϫ mice ( Table 2 ). Skeletal muscle mRNA levels for Mcad and Ucp2 were unchanged in saline-treated Agpat2 Ϫ / Ϫ mice and Ucp2 transcript was signifi cantly decreased by leptin treatment. In contrast, the Lcad mRNA was elevated in the Agpat2 Ϫ / Ϫ mice. Unlike the liver, treatment with leptin did not alter Pk and Chrebp mRNA levels in the skeletal muscle of the Agpat2 Ϫ / Ϫ mice. Pepck mRNA levels were significantly lower in saline-infused Agpat2 Ϫ / Ϫ mice compared with saline-infused wild-type mice and leptin did not correct this abnormality ( Table 2 ) . Taken together these fi ndings suggest that Agpat2 Ϫ / Ϫ mice have decreased basal skeletal muscle fatty acid synthesis rate and that leptin further reduces it.
Hepatocyte specifi c gene deletion of LepR does not affect metabolic actions of leptin in Agpat2
Leptin receptors are present at the CNS and several peripheral tissues, including the liver ( 6 ) . To explore whether the action of leptin was mediated by direct signaling in the
Leptin reduces hepatic levels of phosphorylated-active AKT in Agpat2
؊ / ؊ mice Upon leptin treatment, insulin receptor (IR) was increased in the liver of Agpat2 Ϫ / Ϫ mice whereas the phosphorylated active form of AKT (phosphorylated at serine 473) was reduced ( Fig. 6 ). Concordantly, leptin also reduced phosphorylated GSK-3 ␤ (phosphorylated at serine-9) hepatic levels, indicating lower AKT activation compared with the saline-infused Agpat2 Ϫ / Ϫ mice. Leptin supplementation, therefore, improves insulin sensitivity of Agpat2 Ϫ / Ϫ mice, resulting in decreased circulating insulin levels and lower AKT activation. No changes were noted in PI3K, total AKT, total GSK3 ␤ , or total and phosphorylated ERK1/2 after leptin infusion in the Agpat2 Ϫ / Ϫ mice ( Fig. 6 ).
Leptin-mediated changes in the expression of genes involved in fatty acid synthesis, oxidation, and glucose metabolism in the skeletal muscle of Agpat2 ؊ / ؊ mice Since skeletal muscle is the major target tissue for insulin action, we determined whether leptin infl uences the expression of genes involved in lipid and glucose metabolism in the skeletal muscle of Agpat2 Ϫ / Ϫ mice. In contrast to our fi ndings in liver, saline-infused Agpat2 Ϫ / Ϫ mice had signifi cantly lower Fas and Scd1 but similar Acc1 and Elovl6 triglycerides and cholesterol ( Fig. 7D, E ) in both lipodystrophic mouse groups. The actions of leptin on mRNA levels of selected genes studied in Agpat2 
DISCUSSION
The worldwide epidemic of obesity and related metabolic diseases has fueled new adipose tissue biology research. Among the most important advances in the fi eld has been the discovery of the hormonal actions of WAT ( 2 ) . In CGL patients, the lack of WAT determines insulin resistance, diabetes mellitus, hepatic steatosis, and hyperlipidemia. In these patients ( 28 ) as well as in all tested murine models of CGL ( 27, 50, 51 ) , leptin infusion ameliorates all metabolic complications of lipodystrophy, in spite of persistent WAT defi ciency, indicating that leptin secretion by adipocytes is necessary for normal metabolic regulation. Importantly, the understanding of the mechanism by which leptin ameliorates the metabolic disturbances CGL is still incomplete.
One hypothesis is that leptin partitions body lipids, preventing excessive lipid buildup in nonadipose tissue ( 52 ) . This action seems crucial, since independent evidence suggests that ectopic lipid accumulation directly causes insulin resistance and cellular dysfunction (i.e., lipotoxicity) ( 52 ) .
Then the question is, how does leptin prevent lipotoxicity? It has been suggested that leptin increases fatty acid hepatocyte, we generated hepatocyte specifi c leptin receptor defi cient Agpat2 Ϫ / Ϫ mice by breeding Agpat2 +/ Ϫ mice with mice that harbor fl oxed leptin receptor allele ( LepR f/f ) and Cre recombinase mice driven by albumin promoter (Alb-Cre) ( 7 ) . The resulting Agpat2
;LepR hepato-ko ) mice were infused with leptin or saline for two weeks, and the effects on insulin activity and hepatic lipogenesis were determined. The deletion of the hepatic leptin receptor did not change plasma leptin levels in the Agpat2 Ϫ / Ϫ mice ( Fig. 7A , compare with Fig. 2A ) and did not reverse their lack of white and brown adipose tissue (data not shown). Leptin infusion increased plasma leptin concentrations in both Agpat2
; LepR hepato-ko and Agpat2 Ϫ / Ϫ ; LepR hepato-wt mice, significantly reducing circulating insulin and glucose ( Fig. 7B, C ) , as well as liver Leptin, hepatic steatosis, and insulin resistance in Agpat2 ؊ / ؊ mice 285 but it increases its O -GlcNAcylation ( Fig. 5C ), a reported modifi cation that results in higher ChREBP nuclear translocation and transcriptional activity ( 37 ) . Detailed studies of the posttranslational modifi cation and transcriptional coregulators associated with ChREBP will be necessary to completely understand the actions of leptin on the transcriptional control of hepatic lipogenesis ( 54, 55 ) . Unlike the lipodystrophic A-ZIP/F-1 mice ( 43 ), Agpat2
mice have signifi cantly decreased plasma T4, and this abnormality is signifi cantly corrected by leptin replacement ( Fig. 3A ) . The reported relationship between plasma leptin and thyroid levels is inconsistent ( 56 ) . Interestingly, a new class of selective thyromimetic drugs potently ameliorates liver triglycerides concentration in murine models of hepatic steatosis ( 57, 58 ) , suggesting that normalization of hypothyroxiemic state in Agpat2 Ϫ / Ϫ mice could be a relevant mechanism for leptin's benefi cial actions in the liver of these animals. The precise mechanisms of hypothyroxinemia in Agpat2 Ϫ / Ϫ mice remain unclear and may require further investigation. Similarly, leptin decreases hypercorticosteronemia in Agpat2 Ϫ / Ϫ mice ( Fig. 3B ) and this could, at least partially, oxidation in critical insulin-responsive tissues ( 44, 45 ) . In our studies, leptin supplementation did not increase mRNA levels of genes involved in mitochondrial or peroxisomal fatty acid oxidation in the Agpat2 Ϫ / Ϫ mice ( Table 1 ) . Furthermore, leptin infusion signifi cantly reduced mRNA levels of Fgf21 , a cognate Ppar ␣ target gene ( Table 1 ) , with potent insulin-sensitizing actions in rodents and nonhuman primates as well as humans ( 53 ) Since Ppar ␣ is the master regulator of hepatic fatty oxidation, it is plausible that leptin supplementation results in diminished Ppar ␣ activity and lower liver ␤ -oxidation in the Agpat2 Ϫ / Ϫ mice. Concordantly, hepatic mRNA levels of Ucp2 were reduced upon leptin treatment in these lipodystrophic animals ( Table 1 ) . Alternatively, leptin may prevent lipotoxicity by reducing the exaggerated de novo lipogenesis characteristic of insulin-resistant organisms. Here we report that leptin dramatically decreases the levels of all major lipogenic enzymes in livers of Agpat2 Ϫ / Ϫ mice ( Table 1 , Fig. 4A ) and that this correlates with lower transcriptional activity of ChREBP as estimated by decreased mRNA levels of L-pk , a bona fi de ChREBP target gene ( Table 1 ) . Clearly, leptin does not modify occupancy of L-pk promoter by ChREBP ( Fig. 5B ) liver LepR pool ( 7 ). It is unclear, however, in which nonparenchymal liver cells LepR expression is occurring. The clarifi cation of these questions will require investigation of the different cell types of the liver in their physiological tissue context. In agreement with our observations, the hepatocyte-specifi c deletion of LepR in ob / ob mice did not preclude the ability of infused leptin to increase the circulating levels of insulin-like growth factor binding protein-2 (IGFBP2), a leptin-regulated liver product possibly implicated in leptin metabolic actions ( 66 ) . Thus, a more complete understanding of the metabolic role of leptin in AGPAT2-defi cient mice will require the generation of a total liver-specifi c leptin receptor knockout mouse. This strategy will be also essential to address the nonmetabolic actions of leptin in the liver, such as fi brogenesis and immunomodulation, which seems to be directly dependent on LepR activation in nonparenchymal liver cells (62) (63) (64) . Similarly, in vivo euglycemic hyperinsulinemic clamps will be required to corroborate the insulin-sensitizing effect of leptin in the Agpat2 Ϫ / Ϫ mice and to determine the major site of leptin action in these mice.
In conclusion, the results reported here suggest that 1 ) virtually all the metabolic derangements developed by the Agpat2 Ϫ / Ϫ lipodystrophy mice are derived from leptin deficiency; 2 ) leptin restitution in Agpat2 Ϫ / Ϫ mice may correct explain insulin-sensitizing effects of leptin in these mice. Elevated corticosterone appears to be a common fi nding in murine models of leptin defi ciency ( 59 ) , possibly owing to lack of a direct suppressive effect of leptin on glucocorticoid secretion by corticoadrenal cells ( 60 ) . Interestingly, whereas adrenalectomy dramatically improves both hyperglycemia and hyperinsulinemia in A-ZIP/F-1 lipodystrophic mice, it fails to reduce liver triglyceride concentrations in these animals ( 61 ) , suggesting that hypercorticosteronemia does not play an essential role in the hepatic steatosis associated with severe lipodystrophy. Leptin receptor has been detected in all major liver cell types, including hepatocytes, sinusoidal endothelial, Kupffer, and stellate cells (62) (63) (64) . In contrast, albumin is exclusively expressed in hepatocytes ( 65 ) . Thus, as expected, leptin receptor will still be present in nonparenchymal liver cells of Agpat2 Ϫ / Ϫ ; LepR hepato-ko mice ( Table 3 ) . Upon leptin administration liver LepRb mRNA levels were increased in Agpat2 Ϫ / Ϫ ; LepR hepato-ko mice ( Table 3 ) , strongly suggesting that LepRb is upregulated in nonhepatocyte cell types. This response was also present in wild-type and Agpat2 Ϫ / Ϫ mice ( fatty liver by decreasing de novo hepatic lipogenesis and by elevating thyroxine levels; 3 ) the main transcriptional regulator mediating fatty liver in Agpat2 Ϫ / Ϫ mice is likely ChREBP, and leptin normalizes its nuclear levels, reduces its transcriptional activity, and increases its glycosylation level but does not change its abundance in the L-pk promoter of these mice; and 4 ) the benefi cial metabolic actions of leptin in Agpat2 Ϫ / Ϫ mice do not depend on LepR signaling in hepatocytes.
